2LALERG
Asset
Micro-immunotherapy formulation modulating allergic and inflammatory immune responses
- Stage
- Phase 3
- Modality
- Other
- Target
- Inflammation
- 1
- Indication
- 121
- Trials
- 1
- Developer
Indications
1Seasonal allergy
Phase 3, Completed, NCT02690935, clinicaltrials.gov, 8 Oct 2026
In the full profile
- Targets and what it contains2
- Owner and partners1
- Trials121
- Evidence for its targets2
- Competitors2
- Aging relevance1
- Signals10
Every asset’s record: target, stage, trials and the evidence behind it.